Anticoagulation decisions in patients with atrial fibrillation require individualized risk-benefit assessment
Large-scale real-world research also confirms this picture: a study in which more than 40,000 people met the study criteria shows that people on tirzepatide lost more weight significantly more often than those on semaglutide
Medically, they may be prescribed to treat deficiencies or certain metabolic conditions
Combining semaglutide and metformin can be highly beneficial, especially for individuals with type 2 diabetes, obesity, or cardiovascular risks
For these reasons, a healthy estrogen balance favoring production of 2-hydroxyestrone is important for women's health
You can report through these whistle blower platforms, SAHPRAs 24-hour hotline (0800 204 307) or via our web reporting facility: